OGIVRI CA

OGIVRI (trastuzumab) is indicated for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2... Please enter the 8-digit Drug Identification Number (DIN) as seen on the label of your Ogivri.